Improving vaccine efficacy
The field of vaccine adjuvants has been rapidly evolving since the discovery of the Toll-like receptor (TLR) family of pattern recognition molecules.
Vaccines have proven to be one of the most successful medical interventions against infectious disease. However, as new vaccines are developed, including subunit vaccines, the inclusion of immune response modifiers (IRMs), or adjuvants, to trigger early innate immune responses to aid in the generation or robust and long-lasting adaptive immune responses, is crucial to their effectiveness.
Traditionally, adjuvants have been developed empirically from natural substances found to cause inflammation. When the TLRs are triggered, as series of signaling events occur that lead to activation of the adaptive immune response, specifically the cellular arm.
Documentation shows that TLR-based adjuvants may improve the effectiveness of vaccines by:
- Accelerating the generation of robust, longer lasting immune responses
- Generating antibodies with increased avidity and neutralization capacity
- Enhancing immune responses in individuals with weakened immune systems
- Reducing the amount of antigen and number of doses needed; reducing the cost of vaccination programs
- Activating the cellular ram of the adaptive response, specifically T helper type 1 and cytotoxic T cell responses
3M offers a portfolio of TLR-based assets with differing degrees of clinical readiness. Unlike most other TLR agonists 3M's molecules are small molecules (<500mw) that are easy to manufacture, very stable and can be delivered by multiple routes of administration.
Contact Us for more information: